Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

February 2, 2022

IsoPlexis expands with Asia-Pacific footprint

PHOTO | CONTRIBUTED IsoPlexis' IsoSpark instrument
By Michelle Tuccitto Sullo

Branford-based life science technology company IsoPlexis Corp. announced Wednesday it is expanding in the Asia-Pacific region.

The company has a new office in Shanghai, China, with 5,000 square feet of office space. Staff there will be focused on supporting the company’s Asia-Pacific commercial organization with sales, technical support and general operations.

IsoPlexis also has opened four service labs in large cities in China, including Shanghai, Beijing, Guangzhou and Shenzhen. At these labs, staff will offer support and test services on the company’s platform, along with demonstrations.

The Yale spinout, headquartered at 35 NE Industrial Rd., Branford, provides customers with a platform of instruments and software. The technology captures single-cell protein information then interprets the data for the development of advanced medicines, therapies and vaccines. According to the company, it helps detect “superhero” cells in our bodies that are key to fighting diseases.

Jason Ou is leading the Asia-Pacific office as president and general manager, and he will work to advance the company’s growth in the region. Ou joined IsoPlexis from Tecan, a global provider of automated workflow solutions in the life science and clinical diagnostics markets. 

Peter Siesel, chief commercial officer, said the addition of Ou to the leadership team signals the company’s commitment to growing its international footprint.

“We are confident that his leadership, along with the opening of our new office in Shanghai, will help IsoPlexis to continue its rapid global growth and innovation,” Siesel said.

Researchers worldwide have adopted IsoPlexis’ products, including at biopharmaceutical companies and cancer centers.

Ou said he is looking forward to bringing the company’s “groundbreaking” technology to the region.

“IsoPlexis’ incredible single-cell proteomics technology has the potential to accelerate advanced medicines, and I’m excited and proud to be part of the journey,” Ou said.

Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
 

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF